Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | LTA4H | P09960 | 7/20 | 0.56 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.54 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111159 | 0.90 | ESR1 (0.76) | ESR1ESR2LTA4H | |
| SCHEMBL9966911 | 0.88 | LTA4H (0.62) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL9940230 | 0.88 | LTA4H (0.62) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL6594554 | 0.87 | ESR1 (0.71) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL9940347 | 0.87 | LTA4H (0.61) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7106153 | 0.86 | HRH3 (0.55) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7105849 | 0.84 | ESR1 (0.70) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7108653 | 0.84 | ESR1 (0.65) | ESR1ESR2LTA4HGCGR | |
| SCHEMBL7107783 | 0.84 | ESR1 (0.82) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL13897595 | 0.83 | ESR1 (0.66) | ESR1ESR2LTA4HPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | ESR1 1044/4885ESR2 2130/4885LTA4H 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.